Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a study to develop a protocol on Cognitive behavior therapy (CBT) for asthma-related anxiety that in a consecutive study can be translated to internet-delivered CBT.
Asthma is one of the most common chronic diseases around the world, with a high prevalence of anxiety disorders. Cognitive behaviour therapy (CBT) has been shown to increase psychological well-being for anxiety-related asthma. Our primary aim is to develop a standardized CBT protocol for asthma-related anxiety that can be transferred to internet-delivered CBT. Ten participants will be included in a single-subject multiple baseline design. They will all receive 10-12 sessions of CBT.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CBT for anxiety-related asthma | Experimental | Ten to twelve weekly sessions of CBT targeting enhanced function and decreased symptoms of anxiety. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CBT for anxiety-related asthma | Behavioral | The specific assignments in the intervention will be based on individual behavior analysis for each participant. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Penn State Worry Questionnaire | Change in subjective worry measured with a self-rating scale weekly during 1-3 weeks at baseline and at 10 to 12 weeks post treatment for analysis of effect. | Baseline to 12 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Anxiety Sensitivity Index-3 | Change in anxiety sensitivity measured with a self-rating scale weekly during 1-3 weeks at baseline and at 10 to 12 weeks post treatment for analysis of effect. | Baseline to 12 weeks |
| Short Health Anxiety Inventory (SHAI) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Catarina Almqvist Malmros, MD, PhD | Department of Medical Epidemiology and Biostatistics, Karolinska Institutet | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Medical Epidemiology and Biostatistics, Karolinska Institutet | Stockholm | Sweden |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001249 | Asthma |
| D001008 | Anxiety Disorders |
| ID | Term |
|---|---|
| D001982 | Bronchial Diseases |
| D012140 | Respiratory Tract Diseases |
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
Not provided
Not provided
Single-subject multiple baseline design.
Not provided
Not provided
Not provided
Not provided
Change in health anxiety measured with a self-rating scale weekly during 1-3 weeks at baseline and at 10 to 12 weeks post treatment for analysis of effect.
| Baseline to 12 weeks |
| Asthma Quality of Life Questionnaire | Change in asthma-related quality of life measured with a self-rating scale at pretreatment and at 10 to 12 weeks post treatment for analysis of effect. | Baseline to 12 weeks |
| Asthma control test | Change in asthma control measured with a self-rating scale daily during weekly 1-3 weeks at baseline and at 10 to 12 weeks post treatment for analysis of effect. | Baseline to 12 weeks |
| Catastrophizing about asthma Scale | Change in catastrophizing cognitions about asthma measured with a self-rating scale weekly during 1-3 weeks at baseline and at 10 to 12 weeks post treatment for analysis of effect. | Baseline to 12 weeks |
| Perceived Stress Scale | Change in perceived stress measured with a self-rating scale weekly 1-3 weeks at baseline and at 10 to 12 weeks post treatment for analysis of effect. | Baseline to 12 weeks |
| Patient Health Questionnaire | Change in depression measured with a self-rating scale at baseline and at 10 to 12 weeks post treatment for analysis of effect. | Baseline to 12 weeks |
| D012130 |
| Respiratory Hypersensitivity |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D001523 | Mental Disorders |